Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact email@example.com.
Leptomeningeal metastasis, cancer that has spread to the areas surrounding the brain and spinal cord, has long been a formidable clinical challenge for oncologists. Researchers at Memorial Sloan Kettering Cancer Center have identified the molecular basis of this increasingly prevalent complication of cancer. With the help of a mouse model, researchers have identified a drug strategy that may combat this virtually untreatable condition. This research by Joan Massagué, PhD, Adrienne Boire, MD, PhD, and colleagues, was published in the March 9, 2017 issue of Cell. For more information on this work and to speak with the study authors, contact firstname.lastname@example.org.
Breast cancer affects one in eight women in the United States, with approximately 70 to 80 percent of employed breast cancer survivors returning to work three to eighteen months following diagnosis. Job loss can have devastating financial consequences, including increased risk of bankruptcy and debt. Victoria Blinder, MD, medical oncologist at Memorial Sloan Kettering, conducted a longitudinal study of a racially and ethnically diverse sample of employed women undergoing treatment for stage I-III breast cancer in New York City. For more information on this study, published in Health Affairs on February 6, 2017, and to speak with the study author, contact email@example.com.
The 2016 ASTRO Annual Meeting will take place in Boston from September 25 to 28. Featuring new insights and discoveries from leading institutions around the world, this scientific forum will include presentations and data that could affect the way cancer care is planned and delivered. Memorial Sloan Kettering radiation oncologists are available to comment on meeting news and presentations. Follow the meeting live on Twitter using the hashtag #ASTRO16. For more information or to speak with an expert, contact firstname.lastname@example.org.
A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email email@example.com.
Vice President Joseph Biden visited Memorial Sloan Kettering Cancer Center (MSK) for a roundtable discussion with MSK experts and members of the cancer community. The candid conversation, inspired by the “moonshot” initiative announced by President Obama, was led by Craig Thompson, MD, President and CEO of MSK. MSK’s Carol Brown, MD, Ross Levine, MD, and Robert Sidlow, MD, were also active participants in the discussion. For more information about the event or to request an interview with a MSK roundtable participant, please e-mail firstname.lastname@example.org.
The lack of participation in clinical research may be the Achilles heel facing today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of MSK, only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. For more information or to schedule an interview, please contact email@example.com.
Memorial Sloan Kettering experts are available to comment on new research presented at the American Association for Cancer Research 2016 Annual Meeting including immunotherapy and CAR T cells, exercise oncology, precision medicine and more. For more information and to set up interviews or access photos, email Nicole H. McNamara at firstname.lastname@example.org.
Memorial Sloan Kettering Cancer Center (MSK) is one of six founding medical centers — all leading players in the cancer immunotherapy field — that will join forces in an unprecedented new venture called the Parker Institute for Cancer Immunotherapy. Entrepreneur and philanthropist Sean Parker will announce a $250 million grant to launch the initiative. The funding marks the largest single contribution ever made to the field of immunotherapy. For more information or to schedule an interview, please contact Rebecca Williams at email@example.com.